Earlobe sarcoidosis

Adriane Dore Marie Vorselaars; R. G.M. Keijsers; J. C. Grutters

Earlobe sarcoidosis

Adriane Dore Marie Vorselaars^*
, R. G.M. Keijsers
, J. C. Grutters

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

Abstract

Background: Infliximab, a TNF-α blocking agent, is an upcoming therapeutic option for cases of refractory sarcoidosis. In pulmonary sarcoidosis, changes imaged by ¹⁸F-FDG-PET during infliximab treatment in sarcoidosis patients correlate with signs of clinical improvement. Design: Case-report. Results and conclusions: A patient with severe earlobe sarcoidosis, treated with infliximab, is presented. This case shows that even relatively small extrapulmonary localisations of sarcoidosis can be visualised by ¹⁸F-FDG-PET, and that a decrease of FDG-uptake correlates well with clinical improvement on infliximab treatment.

Original language	English
Pages (from-to)	55-57
Number of pages	3
Journal	Sarcoidosis Vasculitis and Diffuse Lung Diseases
Volume	29
Issue number	1
Publication status	Published - 2012

Keywords

18F-FDG-PET
Infliximab
Sarcoidosis
TNF-α mAb

Cite this

@article{93e385dfc6114d84a4d116238e989267,

title = "Earlobe sarcoidosis",

abstract = "Background: Infliximab, a TNF-α blocking agent, is an upcoming therapeutic option for cases of refractory sarcoidosis. In pulmonary sarcoidosis, changes imaged by 18F-FDG-PET during infliximab treatment in sarcoidosis patients correlate with signs of clinical improvement. Design: Case-report. Results and conclusions: A patient with severe earlobe sarcoidosis, treated with infliximab, is presented. This case shows that even relatively small extrapulmonary localisations of sarcoidosis can be visualised by 18F-FDG-PET, and that a decrease of FDG-uptake correlates well with clinical improvement on infliximab treatment.",

keywords = "18F-FDG-PET, Infliximab, Sarcoidosis, TNF-α mAb",

author = "Vorselaars, \{Adriane Dore Marie\} and Keijsers, \{R. G.M.\} and Grutters, \{J. C.\}",

year = "2012",

language = "English",

volume = "29",

pages = "55--57",

journal = "Sarcoidosis Vasculitis and Diffuse Lung Diseases",

issn = "1124-0490",

publisher = "Mattioli 1885 S.p.A.",

number = "1",

}

TY - JOUR

T1 - Earlobe sarcoidosis

AU - Vorselaars, Adriane Dore Marie

AU - Keijsers, R. G.M.

AU - Grutters, J. C.

PY - 2012

Y1 - 2012

N2 - Background: Infliximab, a TNF-α blocking agent, is an upcoming therapeutic option for cases of refractory sarcoidosis. In pulmonary sarcoidosis, changes imaged by 18F-FDG-PET during infliximab treatment in sarcoidosis patients correlate with signs of clinical improvement. Design: Case-report. Results and conclusions: A patient with severe earlobe sarcoidosis, treated with infliximab, is presented. This case shows that even relatively small extrapulmonary localisations of sarcoidosis can be visualised by 18F-FDG-PET, and that a decrease of FDG-uptake correlates well with clinical improvement on infliximab treatment.

AB - Background: Infliximab, a TNF-α blocking agent, is an upcoming therapeutic option for cases of refractory sarcoidosis. In pulmonary sarcoidosis, changes imaged by 18F-FDG-PET during infliximab treatment in sarcoidosis patients correlate with signs of clinical improvement. Design: Case-report. Results and conclusions: A patient with severe earlobe sarcoidosis, treated with infliximab, is presented. This case shows that even relatively small extrapulmonary localisations of sarcoidosis can be visualised by 18F-FDG-PET, and that a decrease of FDG-uptake correlates well with clinical improvement on infliximab treatment.

KW - 18F-FDG-PET

KW - Infliximab

KW - Sarcoidosis

KW - TNF-α mAb

UR - https://www.scopus.com/pages/publications/84863661348

M3 - Article

C2 - 23311125

AN - SCOPUS:84863661348

SN - 1124-0490

VL - 29

SP - 55

EP - 57

JO - Sarcoidosis Vasculitis and Diffuse Lung Diseases

JF - Sarcoidosis Vasculitis and Diffuse Lung Diseases

IS - 1

ER -

Earlobe sarcoidosis

Abstract

Keywords

Other files and links

Fingerprint

Cite this